Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Cover Page

Cite item

Full Text

Abstract

Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness.

Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age – 48.7±18.1 (median – 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median – 54 vs 21 years; p<0.001), higher body mass index (27.8 vs 23.4; p<0.001), prevalence of chronic diseases (75.3% vs 8.5%; p<0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.8±6.1 vs 4.2±2.7 days; p<0.001) and catarrhal symptoms duration (10.2±5.4 vs 6.1±4.1 days; p<0.001).

Results. During hospitalization 92% of the patients received AVT, 77% – antibiotics, and 16% – corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.7±5.5 vs 11.7±5.5 days; p<0.001) and catarrhal symptoms duration (8.8±5.1 vs 12.0±4.9 days; p<0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.9±7.5 vs 11.7±5.5; p<0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics.

Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.

About the authors

Natalia Yu. Pshenichnaya

National Medical Research Center of Tuberculosis and Infectious Diseases; Central Research Institute of Epidemiology

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-2570-711X

д-р мед. наук, проф., зав. отд. международного сотрудничества, врач-инфекционист группы по оценке качества оказания медицинской помощи при инфекционных болезнях ФГБУ НМИЦ ФПИ, зам. дир. по клинико-аналитической работе ФБУН «ЦНИИ эпидемиологии»

Russian Federation, Moscow

Elena N. Kareva

Sechenov First Moscow State Medical University (Sechenov University); Pirogov Russian National Research Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0001-6861-6512

д-р мед. наук, проф., проф. каф. фармакологии Института биодизайна и моделирования сложных систем ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет), проф. каф. молекулярной фармакологии и радиобиологии ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»

Russian Federation, Moscow

Irina A. Leneva

Mechnikov Research Institute of Vaccines and Serums

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0002-7755-2714

д-р биол. наук, зав. лаб. экспериментальной вирусологии ФГБНУ «НИИВС им. И.И. Мечникова»

Russian Federation, Moscow

Vilya A. Bulgakova

Pirogov Russian National Research Medical University; Central Clinical Hospital

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-4861-0919

д-р мед. наук, проф. каф. факультетской педиатрии педиатрического фак-та ФГАОУ ВО «РНИМУ им. Н.И. Пирогова», зав. отд. научно-информационного развития НИИ педиатрии и охраны здоровья детей ФГБНУ ЦКБ

Russian Federation, Moscow

Irina E. Kravchenko

Kazan State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-4408-7542

д-р мед. наук, проф. каф. инфекционных болезней ФГБОУ ВО «Казанский ГМУ»

Russian Federation, Kazan

Irina V. Nikolaeva

Kazan State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-0104-5895

д-р мед. наук, доц., зав. каф. инфекционных болезней ФГБОУ ВО «Казанский ГМУ»

Russian Federation, Kazan

Antonina I. Grekova

Smolensk State Medical University

Author for correspondence.
Email: pshenichnaya@cmd.su

канд. мед. наук, доц., зав. каф. инфекционных болезней у детей ФГБОУ ВО СГМУ

Russian Federation, Smolensk

Antonina P. Ivanova

Kursk State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0002-1544-382X

канд. мед. наук, доц., доц. каф. инфекционных болезней и эпидемиологии, ФГБОУ ВО КГМУ

Russian Federation, Kursk

Larisa V. Puzyreva

Omsk State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-0495-3645

канд. мед. наук, доц. каф. фтизиатрии, фтизиохирургии и инфекционных болезней ФГБОУ ВО ОмГМУ

Russian Federation, Omsk

Guzel M. Khasanova

Bashkir State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0001-7255-5302

д-р мед. наук, проф., каф. инфекционных болезней с курсом ИДПО ФГБОУ ВО БГМУ

Russian Federation, Ufa

Svetlana N. Orlova

Ivanovo State Medical Academy

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0003-2485-6033

д-р мед. наук, проф., зав. каф. инфекционных болезней, эпидемиологии и дерматовенерологии ФГБОУ ВО ИвГМА

Russian Federation, Ivanovo

Elena P. Tikhonova

Voino-Yasenetsky Krasnoyarsk State Medical University

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0001-6466-9609

д-р мед. наук, проф., зав. каф. инфекционных болезней и эпидемиологии с курсом ПО ФГБОУ ВО «КрасГМУ им. проф. В.Ф. Войно-Ясенецкого»

Russian Federation, Krasnoyarsk

Vladimir A. Petrov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology; Obninsk Institute for Nuclear Power Engineering

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0002-8580-933X

д-р мед. наук, проф., зав. научно-образовательном отд. МРНЦ им. А.Ф. Цыба – филиала ФГБУ «НМИЦ радиологии», зав. каф. инфекционных болезней, общественного здоровья и здравоохранения ИАТЭ НИЯУ МИФИ

Russian Federation, Obninsk

Oleg V. Malinin

Izhevsk State Medical Academy

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0002-3025-0866

канд. мед. наук, доц., зав. каф. инфекционных болезней и эпидемиологии ФГБОУ ВО ИГМА

Russian Federation, Izhevsk

Natalia V. Kolaeva

Sechenov First Moscow State Medical University (Sechenov University)

Email: pshenichnaya@cmd.su

канд. мед. наук, доц., доц. каф. инфекционных болезней ИКМ им. Н.В. Склифосовского ФГАОУ ВО ПМГМУ им. И.М.Сеченова (Сеченовский Университет)

Russian Federation, Moscow

Elena V. Volchkova

Sechenov First Moscow State Medical University (Sechenov University)

Email: pshenichnaya@cmd.su

д-р мед. наук, проф., зав. каф. инфекционных болезней ИКМ им. Склифосовского Н.В. ФГАОУ ВО ПМГМУ им. И.М.Сеченова (Сеченовский Университет)

Russian Federation, Moscow

Nina N. Kanshina

Sechenov First Moscow State Medical University (Sechenov University)

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0002-9608-9737

канд. мед. наук, доц. каф. инфекционных болезней ИКМ им. Склифосовского Н.В. ФГАОУ ВО ПМГМУ им. И.М.Сеченова (Сеченовский Университет)

Russian Federation, Moscow

Vladimir P. Chulanov

National Medical Research Center of Tuberculosis and Infectious Diseases; Sechenov First Moscow State Medical University (Sechenov University)

Email: pshenichnaya@cmd.su
ORCID iD: 0000-0001-6303-9293

д-р мед. наук, проф., зам. дир. по научной работе и инновационному развитию ФГБУ НМИЦ ФПИ, проф. каф. инфекционных болезней института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)

Russian Federation, Moscow

References

  1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-60. doi: 10.23750/abm.v91i1.9397
  2. Yu C, Zhang Z, Guo Y, et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. J Med Virol. 2021;93(1):472-80. doi: 10.1002/jmv.26260
  3. Rinaldi G, Paradisi M. An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreak. medRxiv. Published online 2020. doi: 10.1101/2020.04.18.20070912
  4. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 12 от 21.09.2021. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf. Ссылка активна на 28.09.2021 [Russian Ministry of Health Interim Guidelines for the Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19). Version 12 from 21.09.2021. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf. Accessed: 28.09.2021 (in Russian)].
  5. Negrut N, Codrean A, Hodisan I, et al. Efficiency of antiviral treatment in COVID-19. Exp Ther Med. 2021;21(6):648. doi: 10.3892/etm.2021.10080
  6. WHO. COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available at: https://covid19.who.int/. Accessed: 28.09.2021.
  7. Статистика распространения коронавируса в России. Режим доступа: https://coronavirus-monitor.info/country/russia. Ссылка активна на 28.09.2021 [Coronavirus spread statistics in Russia. Available at: https://coronavirus-monitor.info/country/russia. Accessed: 28.09.2021 (in Russian)].
  8. World Health Organization. A coordinated global research roadmap: 2019 novel coronavirus. March 2020. Available at: https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1. Accessed: 28.09.2021.
  9. RECOVERY Trial. Available at: https://www.recoverytrial.net. Accessed: 28.09.2021.
  10. Group RC; Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40. doi: 10.1056/NEJMoa2022926
  11. Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England). 2020;396(10259):1345-52. doi: 10.1016/S0140-6736(20)32013-4
  12. Consortium WHOST; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184
  13. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med. 2020;383(19):1813-26. doi: 10.1056/NEJMoa2007764
  14. Прикладная фармакоэпидемиология: учебник. Под ред. В.И. Петрова. М.: ГЭОТАР-Медиа, 2008 [Prikladnaia farmakoepidemiologiia: uchebnik. Pod red. VI Petrova. Moscow: GEOTAR-Media, 2008 (in Russian)].
  15. Guan W, Du QL, Jiang HM, et al. Comparison of inhibitory effects of arbidol and Lianhuaqingwen capsules on middle east respiratory syndrome coronavirus in vitro and in vivo. Guangdong Med J. 2018;39(23):3454-58. doi: 10.13820/j.cnki.gdyx.20181221.014
  16. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-36. doi: 10.1001/jama.2020.6019
  17. Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20(1):954. doi: 10.1186/s12879-020-05698-w
  18. Leneva I, Kartashova N, Poromov A, et al. Antiviral Activity of Umifenovir In vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus. Viruses. 2021;13(8):1665. doi: 10.3390/v13081665
  19. Ge Y, Tian T, Huang S, et al. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv. Published online 2020. doi: 10.1101/2020.03.11.986836
  20. Ghaderkhani S, salami Khaneshan A, Salami A, et al. Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial. Res Sq. Published online 2021. doi: 10.21203/rs.3.rs-91430/v1
  21. Zeng H, He X, Liu W, et al. Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients. Cardiol Discov. 2021;1(1):37-43. doi: 10.1097/CD9.0000000000000014
  22. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6
  23. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/science.abd4570
  24. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585
  25. Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19(2):181-93. doi: 10.1016/j.chom.2016.01.007
  26. Berger ML, Dreyer N, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012;15(2):217-30. doi: 10.1016/j.jval.2011.12.010

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. COVID-19 cases in the Russian Federation during the study period (black line) and the number of patients included in the study.

Download (85KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies